A new study by researchers at Hasbro Children’s Hospital, the pediatric division of Rhode Island Hospital, and Mount Sinai Hospital, New York, offers new insight into the role that the cystic fibrosis gene plays in the development of gastrointestinal disease.

New microscopic pictures show the first-ever physical evidence of interaction between two proteins involved in Cystic Fibrosis (CF) disease.

Treatment with ibuprofen is associated with a significantly slower rate of decline in lung function in children and adolescents with cystic fibrosis, according to a new study.

Commenting on a study of lung transplantation for children with cystic fibrosis, a leading pediatric pulmonologist calls the study “startling” in an editorial in this week’s New England Journal of Medicine that accompanies the study.

Lung transplantation, the therapy almost every cystic fibrosis patient (CF) considers at some point to prolong survival, rarely helps children with the disease live longer and, in fact, often increases their risk of dying, University of Utah researchers conclude in the most extensive study of the issue to date.

New clinical standards on the treatment of patients with cystic fibrosis (CF) have been released following an exhaustive review of all available literature.

Cystic fibrosis (CF) is an inherited disease caused by mutations in the CFTR gene. Each mutation has number of effects on the cells of the lungs.

The most important clinical problem for people with cystic fibrosis (CF) is inflammation of their lungs. The inflammation then plays a role in further damaging the tissues. Consequently, people have wondered whether giving non-steroidal anti-inflammatory drugs (NSAIDs) to patients with CF will reduce lung inflammation.

Tiny new laboratory tools termed microfluidic devices are helping biomedical researchers to better understand the physiological and chemical processes underlying high blood pressure, stroke, sickle cell disease and other disorders, according to an article scheduled for the Sept.10 issue of Chemical & Engineering News, ACS’ weekly newsmagazine.

The results of a clinical trial, published in late August in the Journal of Pediatrics, indicates that, when used as part of routine therapy, high-dose ibuprofen is safe, and effective in slowing down lung disease in children with cystic fibrosis (CF).

BlueStar and MMF Cash Drawer teamed up recently for a Cystic Fibrosis Foundation fundraiser at BlueStar's national headquarters.

In a study of children with cystic fibrosis, French researchers found evidence of very early onset defective bone mineralization in the lumbar spine that was not caused by either nutritional status or lung disease. The lumbar spine is that part of the back between the ribs and the pelvis.